Who will be happy in Russia from 44 characters in a cryptocode?

11 September 2019

Two months after the start of the first stage of labeling (labeling of drugs for high cost nosology), the Russian government approved a new cryptocode length. On August 30, Dmitry Medvedev signed amendments to Decree of the Government of the Russian Federation No. 1556 "On approval of the Regulation on the system for monitoring the movement of drugs for medical use." This means that manufacturers have to reconfigure equipment from 88 characters to 44.

The pharmaceutical industry insisted on 20 or less characters, but, as practice shows, it was not heard. Will manufacturers succeed, reorganizing in less than a month to meet new requirements, or will the current situation inevitably lead to destabilization of drug supply in the Russian Federation?

The question is rhetorical: why are there 44 characters and will this save the situation? ..

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK